Biotransformación de diterpenoides por hongos filamentosos nativos :

IP 1203-12-10404Incluye anexos.Javergraf. -- p. ; 28 cm. -- Contribucion al estudio de los hongos filamentosos en la zona de frailejones del;paramo de Guasca - Colombia / Adriana Chitiva ... [et al.]--p.193 -- En: Congreso Nacional de Ciencias;Biologicas. (37 : 2001 oct : Cartagena de Indias, Colombia) --[s.l : s.n], 2001 -- p. ; 23 cm. -- Produccion;de metabolitos secundarios de la cepa EB-406-05 / Ruben DarioTorrenegra,Giovana Salamanca. -- p. 193 -- En:;Congreso Nacional de Ciencias Biologicas. (37 : 2001 oct :Cartagena de Indias, Colombia) -- [s.l : s.n],;2001 -- p. ; 23 cm -- Una cepa nativa colombiana de Penicilliumverrucosumcomo fuente de acido micofenolico /;Ruben D. Torrenegra, Jose E. Baquero. -- p. 108 -- En: CongresoItalo-latinoamericano de etnomedicina Nuno;Alvares Pereira. (12 : 2003 sep. 8-12 : Rio de Janeiro) --[s.l: s.n], 2003 -- p. ; 28 cm. -- Mohos de los;paramos de Guasca y El tablazo / Adriana J. Chitiva. -- En: Congreso la Investigacion en la Pontificia;Universidad Javeriana. (7 : 2003 ago. 26-29 : Bogotá) -- [s.l:s.n], 2003-- p. ; 28 cm. -- Biotransformacion;de diterpenos y voacangina, evaluacion de metabolitos secundarios del Aspergillus niger 511 y su actividad;PONENCIA(S) EN CONGRESO: Metabolitos secundarios del Aspergillusniger 511y su actividad antimicrobiana /;R.D. Torrenegra, P.M. Daza. -- p. 103-104 -- En: CongresoNacional de Fitoquimica. (7 : 2002 : Bogotá) --;antimicrobiana / Ruben D. Torrenegra G. -- En: Congreso laInvestigacion en la Pontificia Universidad;Javeriana. (7 : 2003 ago. 26-29 : Bogotá) -- [s.l : s.n],2003-- p. ; 28cm.;Bogotá : Javergraf., 2002 -- p. ; 28 cm. -- Un metabolitosecundario antimicrobiano / J.E. Baquero, R.D.;Torrenegra, M. Bayona. -- p.124-125 -- En: Congreso NacionaldeFitoquimica. (7 : 2002 : Bogotá) -- Bogotá

Expresión de la enzima Iduronato Sulfatasa en pichia pastoris :estudios de su modelo de glicosilación. Posible uso de la enzima en terapia de reemplazo enzimático

IP 1203-12-10410Incluye anexos.Colombia / P. Sarmiento ... [et al.] -- p. 38 -- En: International Symposium on Novel Therapies for Lysosomal;Storage Disroders. (2001 Nov. 29-Dec. 1 : Canela, Brazil)-- [s.l : s.n],2001 -- p. ; 28 cm. -- Prediccion;computacional de las estructuras secundaria y terciaria delaiduronato 2-sulfato sulfatasa (ids) y modelos de;PONENCIA(S) EN CONGRESO: Expression of the human recombinant iduronate 2-sulfate sulfatase (hrids) in Pichia;Pastoris / Patricia Landazuri ... [et al.] -- En: Annual WorldSymposium on Lysosomal Storage Disorders (2002;: Baltimore) -- [s.l : s.n], 2002 -- p. ; 28 cm. -- Preliminarymolecularstudy of morquio syndrome in;de la iduronato-2 sulfato sulfatasa humana recombinante funcionalmente activa en Escherichia coli / Patricia;Landazuri. [et al.] -- p. 115 -- En: Congreso Nacional deCiencias Biologicas. (37 : 2002 oct. 1-4 : San Juan;de Pasto, Colombia). -- [s.l : s.n], 2002 -- p. ; 22 cm. -'- Estudios computacionales sobre las glicosilaciones;de la iduronato-2 sulfatasa / L. Lareo, M.A. Gutierrez, L.A. Barrera. -- p. 41 -- En: Congreso Latinoamericano;de Errores Innatos del Metabolismo y Pesquisa Neonatal, Encuentro Internacional en Screening Neonatal (3, 3 :;2001 oct. 21-24 : Cartagena, Colombia) -- [s-l : s.n], 2001 --p. ; 28 cm.;su sitio activo / Edgar Reyes, Leonardo Lareo, Luis AlejandroBarrera. --En: Congreso Nacional de Genetica;Humana. (27 : 2002 nov. 20-23 : Veracruz, Mexico). -- [s.l:s.n], 2002 --p. ; 28 cm. -- Expresion trasient

Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave : the global UNITE-COVID study

Purpose To accommodate the unprecedented number of critically ill patients with pneumonia caused by coronavirus disease 2019 (COVID-19) expansion of the capacity of intensive care unit (ICU) to clinical areas not previously used for critical care was necessary. We describe the global burden of COVID-19 admissions and the clinical and organizational characteristics associated with outcomes in critically ill COVID-19 patients. Methods Multicenter, international, point prevalence study, including adult patients with SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) and a diagnosis of COVID-19 admitted to ICU between February 15th and May 15th, 2020. Results 4994 patients from 280 ICUs in 46 countries were included. Included ICUs increased their total capacity from 4931 to 7630 beds, deploying personnel from other areas. Overall, 1986 (39.8%) patients were admitted to surge capacity beds. Invasive ventilation at admission was present in 2325 (46.5%) patients and was required during ICU stay in 85.8% of patients. 60-day mortality was 33.9% (IQR across units: 20%-50%) and ICU mortality 32.7%. Older age, invasive mechanical ventilation, and acute kidney injury (AKI) were associated with increased mortality. These associations were also confirmed specifically in mechanically ventilated patients. Admission to surge capacity beds was not associated with mortality, even after controlling for other factors. Conclusions ICUs responded to the increase in COVID-19 patients by increasing bed availability and staff, admitting up to 40% of patients in surge capacity beds. Although mortality in this population was high, admission to a surge capacity bed was not associated with increased mortality. Older age, invasive mechanical ventilation, and AKI were identified as the strongest predictors of mortality

Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set

Background: The COVID-19 pandemic presented major challenges for critical care facilities worldwide. Infections which develop alongside or subsequent to viral pneumonitis are a challenge under sporadic and pandemic conditions; however, data have suggested that patterns of these differ between COVID-19 and other viral pneumonitides. This secondary analysis aimed to explore patterns of co-infection and intensive care unit-acquired infections (ICU-AI) and the relationship to use of corticosteroids in a large, international cohort of critically ill COVID-19 patients.Methods: This is a multicenter, international, observational study, including adult patients with PCR-confirmed COVID-19 diagnosis admitted to ICUs at the peak of wave one of COVID-19 (February 15th to May 15th, 2020). Data collected included investigator-assessed co-infection at ICU admission, infection acquired in ICU, infection with multi-drug resistant organisms (MDRO) and antibiotic use. Frequencies were compared by Pearson's Chi-squared and continuous variables by Mann-Whitney U test. Propensity score matching for variables associated with ICU-acquired infection was undertaken using R library MatchIT using the "full" matching method.Results: Data were available from 4994 patients. Bacterial co-infection at admission was detected in 716 patients (14%), whilst 85% of patients received antibiotics at that stage. ICU-AI developed in 2715 (54%). The most common ICU-AI was bacterial pneumonia (44% of infections), whilst 9% of patients developed fungal pneumonia; 25% of infections involved MDRO. Patients developing infections in ICU had greater antimicrobial exposure than those without such infections. Incident density (ICU-AI per 1000 ICU days) was in considerable excess of reports from pre-pandemic surveillance. Corticosteroid use was heterogenous between ICUs. In univariate analysis, 58% of patients receiving corticosteroids and 43% of those not receiving steroids developed ICU-AI. Adjusting for potential confounders in the propensity-matched cohort, 71% of patients receiving corticosteroids developed ICU-AI vs 52% of those not receiving corticosteroids. Duration of corticosteroid therapy was also associated with development of ICU-AI and infection with an MDRO.Conclusions: In patients with severe COVID-19 in the first wave, co-infection at admission to ICU was relatively rare but antibiotic use was in substantial excess to that indication. ICU-AI were common and were significantly associated with use of corticosteroids